Last reviewed · How we verify
MSL-109
At a glance
| Generic name | MSL-109 |
|---|---|
| Also known as | Monoclonal antibodies |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS (PHASE2)
- Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) (PHASE2, PHASE3)
- A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) (PHASE2)
- A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria (PHASE1)
- Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease (PHASE1, PHASE2)
- A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSL-109 CI brief — competitive landscape report
- MSL-109 updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI